Bicara Therapeutics Inc. Common Stock
Symbol: BCAX (NASDAQ)
Company Description:
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
- Today's Open: $17.15
- Today's High: $17.15
- Today's Low: $16.36
- Today's Volume: 62
- Yesterday Close: $17.06
- Yesterday High: $17.4068
- Yesterday Low: $16.31
- Yesterday Volume: 978.88K
- Last Min Volume: 5
- Last Min High: $16.96
- Last Min Low: $16.36
- Last Min VWAP: $16.96
- Name: Bicara Therapeutics Inc. Common Stock
- Website: https://www.bicara.com
- Listed Date: 2024-09-13
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0002023658
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $888.00M
- Round Lot: 100
- Outstanding Shares: 54.61M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-10-20 | 4 | View |
2025-10-16 | 4 | View |
2025-10-16 | 144 | View |
2025-10-15 | 4 | View |
2025-10-15 | 144 | View |
2025-10-15 | 144 | View |
2025-10-14 | 144 | View |
2025-10-10 | 4 | View |
2025-10-10 | 4 | View |
2025-10-09 | 144 | View |
2025-10-09 | 144 | View |
2025-10-08 | 4 | View |
2025-10-08 | 4 | View |
2025-10-08 | 144 | View |
2025-10-07 | 144 | View |
2025-10-07 | 144 | View |
2025-10-06 | 144 | View |
2025-10-06 | 144 | View |
2025-10-03 | S-3 | View |
2025-10-01 | 4 | View |